title: The SAMe-TT2R2 score and decision-making between a vitamin K antagonist or a non-vitamin K antagonist oral anticoagulant in patients with atrial fibrillation.
abstract: Oral anticoagulation therapy is essential in patients with atrial fibrillation and clinicians need guidance on decision-making between the vitamin K antagonists (VKA), e.g. warfarin, or non-vitamin K antagonist oral anticoagulants. Observational studies have shown that patients who receive VKA therapy spend a significant percentage of their time with international normalized ratio values outside of the therapeutic range (time in therapeutic range, TTR <60%.) Recently, a clinical score has been developed with commonly encountered clinical features, the SAMe-TT2R2 score, to help decision-making with regard to whether a patient is likely to do well, or not, with a VKA. Those with a SAMe-TT2R2 score of 0-1 are likely to do well on a VKA, while those with a SAMe-TT2R2 score ≥ 2 are on probability going to achieve suboptimal TTR. In this article, we provide an overview of the main published retrospective and prospective studies that have validated the SAMe-TT2R2 score and its value for decision-making in daily clinical practice.
authors.affiliation: a Department of Cardiology, Hospital Universitario Virgen de la Arrixaca , University of Murcia , Murcia , Spain.|b Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca (IMIB) , Murcia , Spain.
authors.forename: María Asunción
authors.initials: MA
authors.lastname: Esteve-Pastor
authors.affiliation: b Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca (IMIB) , Murcia , Spain.|c Department of Hematology and Clinical Oncology, Hospital Universitario Morales Meseguer , University of Murcia , Murcia , Spain.
authors.forename: Vanessa
authors.initials: V
authors.lastname: Roldán
authors.affiliation: a Department of Cardiology, Hospital Universitario Virgen de la Arrixaca , University of Murcia , Murcia , Spain.|b Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca (IMIB) , Murcia , Spain.
authors.forename: Mariano
authors.initials: M
authors.lastname: Valdés
authors.affiliation: d University of Birmingham Institute of Cardiovascular Sciences , City Hospital , Birmingham , UK.|e Department of Clinical Medicine , Aalborg Thrombosis Research Unit, Aalborg University , Aalborg , Denmark.
authors.forename: Gregory Y H
authors.initials: GY
authors.lastname: Lip
authors.affiliation: a Department of Cardiology, Hospital Universitario Virgen de la Arrixaca , University of Murcia , Murcia , Spain.|b Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca (IMIB) , Murcia , Spain.
authors.forename: Francisco
authors.initials: F
authors.lastname: Marín
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D019934:International Normalized Ratio; D014812:Vitamin K / Q000037:antagonists & inhibitors; D014859:Warfarin / Q000627:therapeutic use*
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents; D014812:Vitamin K; D014859:Warfarin
keywords: CHA2DS2-VASc; NOAC; SAMe-TT2R2; atrial fibrillation; vitamin K antagonists